Skip to main content
SpringerLink
Log in

Treatment of negative and cognitive symptoms

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Persistent negative symptoms and cognitive dysfunction are a major cause of chronic disability in schizophrenia. Atypical antipsychotics such as clozapine, risperidone, and olanzapine induce significantly greater improvement in negative symptoms than that which is obtained with conventional agents. However, it remains unclear whether these agents treat core negative symptoms of schizophrenia, or simply induce less secondary psychopathology. A second approach for treatment of persistent negative symptoms is the use of N-methyl-D-aspartate (NMDA) receptor-stimulating agents, such as glycine, D-serine or D-cycloserine. These agents, when added to conventional or atypical antipsychotics, may induce significant additional reduction in both negative and cognitive symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Lancon C, Aghababian V, Llorca PM, et al.: Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr Scand 1998, 98:369–376.

    PubMed  CAS  Google Scholar 

  2. Bryson G, Bell M, Greig T, et al.: Internal consistency, temporal stability and neuropsychological correlates of three cognitive components of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 1999, 38:27–35.

    Article  PubMed  CAS  Google Scholar 

  3. Smith DA, Mar CM, Turoff BK: The structure of schizophrenic symptoms: a meta-analytic confirmatory factor analysis. Schizophr Res 1998, 31:57–70.

    Article  PubMed  CAS  Google Scholar 

  4. White L, Harvey PD, Opler L, et al.: Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group. Psychopathology 1997, 30:263–274.

    Article  PubMed  CAS  Google Scholar 

  5. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233–255.

    PubMed  CAS  Google Scholar 

  6. Mohamed S, Paulsen JS, O’Leary D, et al.: Generalized cognitive deficits in schizophrenia. Arch Gen Psychiatry 1999, 56:749–754.

    Article  PubMed  CAS  Google Scholar 

  7. Shelley AM, Silipo G, Javitt DC.: Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr Res 1999, 37:65–79.

    Article  PubMed  CAS  Google Scholar 

  8. March L, Cienfuegos A, Goldbloom L, et al.: Normal time course of auditory recognition in schizophrenia, despite impaired precision of the auditory sensory ("echoic") memory code. J Abnorm Psychol 1999, 108:69–75.

    Article  PubMed  CAS  Google Scholar 

  9. Cienfuegos A, March L, Shelley AM, et al.: Impaired categorical perception of synthetic speech sounds in schizophrenia. Biol Psychiatry 1999, 45:82–88.

    Article  PubMed  CAS  Google Scholar 

  10. Javitt DC, Grochowski S, Shelley AM, et al.: Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/ interdeviant interval. Electroencephalogr Clin Neurophysiol 1998, 108:143–153.

    Article  PubMed  CAS  Google Scholar 

  11. Dickerson F, Bornow JJ, Ringel N, et al.: Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up. Schizophr Res 1999, 37:13–20.

    Article  PubMed  CAS  Google Scholar 

  12. Ho BC, Nopoulos P, Flaum M, et al.: Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998, 155:1196–1201.

    PubMed  CAS  Google Scholar 

  13. Buchanan RW, Breier A, Kirkpatrick B, et al.: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998, 155:751–760. This study evaluates the degree to which clozapine improves primary negative symptoms of schizophrenia. Despite improvement in positive symptoms, no improvement in core negative (deficit) symptoms was observed.

    PubMed  CAS  Google Scholar 

  14. Breier AF, Malhotra AK, Su TP, et al.: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999, 156:294–8.

    PubMed  CAS  Google Scholar 

  15. Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994, 36:717–725.

    Article  PubMed  CAS  Google Scholar 

  16. Lee MA, Jayathilake K, Meltzer HY: A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 1999, 37:1–11.

    Article  PubMed  CAS  Google Scholar 

  17. Galletly CA, Clark CR, McFarlane AC, et al.: Effects of clozapine for non-treatment-resistant patients with schizophrenia. Psychiatr Serv 1999, 50:101–103.

    PubMed  CAS  Google Scholar 

  18. Lindenmayer JP, Iskander A, Park M, et al.: Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998, 59:521–527.

    PubMed  CAS  Google Scholar 

  19. McGurk SR: The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999, 60:24–29.

    PubMed  CAS  Google Scholar 

  20. Keefe RS, Silva SG, Perkins DO, et al.: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201–222.

    PubMed  CAS  Google Scholar 

  21. Umbricht D, Javitt D, Novak G, et al.: Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998, 44:716–725. This study and Schall et al. [22•] are the first to use neurophysiologic measures to investigate mechanisms of clozapine-induced improvements in cognitive functioning. Both indicate that clozapine induces significant improvement in attention-dependent processing, but does not significantly reverse earlier perceptual processing dysfunction.

    Article  PubMed  CAS  Google Scholar 

  22. Schall U, Catts SV, Chaturvedi S, et al.: The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. Int J Neuropsychopharmacol 1998, 1:19–29. This study and Umbricht et al. [21•] are the first to use neurophysiologic measures to investigate mechanisms of clozapine-induced improvements in cognitive functioning. Both indicate that clozapine induces significant improvement in attention-dependent processing, but does not significantly reverse earlier perceptual processing dysfunction.

    Article  PubMed  CAS  Google Scholar 

  23. Chouinard G, Kopala L, Labelle A, et al.: Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Can J Psychiatry 1998, 43:1018–1025.

    PubMed  CAS  Google Scholar 

  24. Bondolfi G, Dufour H, Patris M, et al.: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998, 155:499–504.

    PubMed  CAS  Google Scholar 

  25. Tollefson GD, Beasley CM, Jr., Tran PV, et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry, 1997, 154:457–465.

    PubMed  CAS  Google Scholar 

  26. Breier A, Hamilton SH: Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999, 45:403–411. This study evaluated the degree to which olanzapine affected negative symptoms in treatment-resistant, as compared to treatment responsive, patients.

    Article  PubMed  CAS  Google Scholar 

  27. Conley RR, Tamminga CA, Bartko JJ, et al.: Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry, 1998, 155:914–920.

    PubMed  CAS  Google Scholar 

  28. Sanger TM, Lieberman JA, Tohen M, et al.: Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999, 156:79–87.

    PubMed  CAS  Google Scholar 

  29. Henderson DC, Nasrallah RA, Goff DC: Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 1998, 59:585–588.

    PubMed  CAS  Google Scholar 

  30. Conley RR, Tamminga CA, Kelly DL, et al.: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999, 46:73–77.

    Article  PubMed  CAS  Google Scholar 

  31. Allan ER, Sison CE, Alpert M, et al.: The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull 1998, 34:71–74.

    PubMed  CAS  Google Scholar 

  32. Malla AK, Norman RM, Kotteda V, et al.: Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome. Clin Ther 1999, 21:806–817.

    Article  PubMed  CAS  Google Scholar 

  33. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301–1308.

    PubMed  CAS  Google Scholar 

  34. Abi-Saab WM, D’Souza DC, Moghaddam B, et al.: The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry, 1998, 31(Suppl 2):104–109.

    Article  PubMed  CAS  Google Scholar 

  35. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al.: Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106–118.

    Article  PubMed  CAS  Google Scholar 

  36. Heresco-Levy U, Javitt DC, Ermilov M, et al.: Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1998, 1:131–136.

    Article  PubMed  Google Scholar 

  37. Heresco-Levy U, Javitt DC, Ermilov M, et al.: Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999, 56:29–36. This study provides the largest sample of patients treated with highdose (60 g/d) glycine. Twenty-two patients were treated in a doubleblind, placebo-controlled, crossover design. Highly significant reductions were observed in negative and cognitive symptoms, along with lesser reductions in positive symptoms.

    Article  PubMed  CAS  Google Scholar 

  38. Potkin SG, Jin Y, Bunney BG, et al.: Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999, 156:145–147.

    PubMed  CAS  Google Scholar 

  39. Javitt DC, Frusciante MJ: Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse. Psychopharmacol 1996, 3:207–210.

    Google Scholar 

  40. Javitt DC, Sershen H, Hashim A, et al.: Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacol 1997, 17:202–204.

    Article  CAS  Google Scholar 

  41. Supplisson S, Bergman C: Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 1997, 17:4580–4590.

    PubMed  CAS  Google Scholar 

  42. Bergeron R, Meyer TM, Coyle JT, et al.: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci U S A 1998, 95:15730–15734.

    Article  PubMed  CAS  Google Scholar 

  43. Danysza W, Parsons CG: Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 1998, 50:597–664.

    Google Scholar 

  44. Berger AJ, Dieudonne S, Ascher P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 1998, 80:3336–40.

    PubMed  CAS  Google Scholar 

  45. Javitt DC, Balla A, Sershen H, et al.: Reversal of phencyclidineinduced effects by glycine and glycine transport inhibitors. Biol Psychiatry 1999, 45:668–679. This study presents initial findings regarding the effects of glycine transport inhibitors on PCP-induced symptoms in rodents, and discusses the potential use of glycine transport inhibitors in the treatment of schizophrenia.

    Article  PubMed  CAS  Google Scholar 

  46. Shoham S, Javitt DC, Heresco-Levy U: High dose glycine nutrition affects glial cell morphology in rat hippocampus and cerebellum. Int J Neuropsychopharmacol 1999, 2:35–40.

    Article  PubMed  CAS  Google Scholar 

  47. Tsai G, Yang P, Chung LC, et al.: D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998, 44:1081–1089. This study is the first to evaluate the effects of D-serine on negative symptoms in schizophrenia. Highly significant effects on negative, positive, and cognitive symptoms were observed.

    Article  PubMed  CAS  Google Scholar 

  48. Heresco-Levy U, Javitt DC, Ermilov M, et al.: Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1998, 1:131–136.

    Article  PubMed  Google Scholar 

  49. Goff DC, Tsai G, Levitt J, et al.: A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry, 1999, 56:21–27. This is the largest study to date of D-cycloserine in the treatment of schizophrenia. Significant reductions in negative symptoms were observed.

    Article  PubMed  CAS  Google Scholar 

  50. Goff DC, Henderson DC, Evins AE, et al.: A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999, 45:512–514.

    Article  PubMed  CAS  Google Scholar 

  51. Moghaddam B, Adams BW: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349–1352. This study utilizes a phencyclidine model in rats to investigate mechanisms of cognitive dysfunction. Based on these findings, it is suggested that metabotropic agonists or AMPA/kainate antagonists may be particularly beneficial in schizophrenia.

    Article  PubMed  CAS  Google Scholar 

  52. Farber NB, Hanslick J, Kirby C, et al.: Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 1998, 18:57–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, 10962, Orangeburg, NY, USA

    Daniel C. Javitt MD, PhD

Authors
  1. Daniel C. Javitt MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Javitt, D.C. Treatment of negative and cognitive symptoms. Curr Psychiatry Rep 1, 25–30 (1999). https://doi.org/10.1007/s11920-999-0007-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-999-0007-z

Keywords

Search

Navigation